Segall Bryant & Hamill LLC Increases Stock Position in Guardant Health, Inc. $GH

Segall Bryant & Hamill LLC lifted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 57.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,147 shares of the company’s stock after buying an additional 111,822 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.24% of Guardant Health worth $19,066,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Norges Bank bought a new stake in Guardant Health during the second quarter worth about $64,136,000. Franklin Resources Inc. lifted its holdings in shares of Guardant Health by 78.2% during the second quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after purchasing an additional 1,018,144 shares during the last quarter. Invesco Ltd. boosted its position in shares of Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares in the last quarter. Nikko Asset Management Americas Inc. grew its stake in shares of Guardant Health by 49.6% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock worth $105,623,000 after buying an additional 673,438 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Guardant Health in the 3rd quarter worth approximately $39,523,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Up 1.2%

NASDAQ GH opened at $93.30 on Wednesday. Guardant Health, Inc. has a 52 week low of $34.88 and a 52 week high of $120.74. The firm has a market capitalization of $12.24 billion, a P/E ratio of -28.19 and a beta of 1.67. The company has a 50-day moving average price of $105.92 and a 200-day moving average price of $88.41.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. During the same quarter last year, the firm posted ($0.62) earnings per share. The company’s revenue was up 39.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Activity

In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the sale, the chief executive officer owned 168,223 shares in the company, valued at $17,671,826.15. This represents a 37.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Terilyn J. Monroe sold 8,571 shares of Guardant Health stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total value of $977,865.39. Following the transaction, the insider directly owned 20,990 shares in the company, valued at approximately $2,394,749.10. The trade was a 28.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 379,344 shares of company stock worth $39,734,840. Company insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. JPMorgan Chase & Co. boosted their target price on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Wells Fargo & Company lifted their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Evercore set a $110.00 price objective on shares of Guardant Health in a research report on Friday, February 20th. TD Cowen raised their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Finally, Robert W. Baird started coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 target price on the stock. Twenty-one research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $122.57.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.